Literature DB >> 10049288

Penetration of meropenem in lung, bronchial mucosa, and pleural tissues.

B Byl1, F Jacobs, I Roucloux, P de Franquen, M Cappello, J P Thys.   

Abstract

Lung, bronchial mucosa, and pleural tissue samples were obtained from 14 patients undergoing lung surgery 1 to 5 h after administration of 1 g of meropenem. The mean (range) peak concentrations of meropenem were 3.9 (0.2 to 8.2), 6.6 (3.0 to 13.3), and 2.8 (0.6 to 7.8) mg/kg of tissue, respectively, exceeding the MICs at which 90% of isolates are inhibited for most respiratory pathogens.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10049288      PMCID： PMC89181     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.

Authors:  E Vallée; E Azoulay-Dupuis; J J Pocidalo; E Bergogne-Bérézin
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

3.  Meropenem pharmacokinetics and penetration into an inflammatory exudate.

Authors:  R Wise; M Logan; M Cooper; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.

Authors:  H C Kelly; M Hutchison; S J Haworth
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

5.  Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study.

Authors:  B I Davies; F P Maesen; R Gubbelmans
Journal:  J Antimicrob Chemother       Date:  1989-05       Impact factor: 5.790

6.  Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia.

Authors:  E Azoulay-Dupuis; E Vallée; J P Bedos; M Muffat-Joly; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

Authors:  E Azoulay-Dupuis; J P Bedos; E Vallée; D J Hardy; R N Swanson; J J Pocidalo
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

8.  Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy.

Authors:  G Benoni; L Cuzzolin; C Bertrand; V Puchetti; G Velo
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

9.  Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia.

Authors:  B Veber; E Vallée; J M Desmonts; J J Pocidalo; E Azoulay-Dupuis
Journal:  J Antimicrob Chemother       Date:  1993-09       Impact factor: 5.790

10.  Therapeutic efficacy of cefadroxil and cephalexin for pneumonia in a rat test model.

Authors:  D R Chisholm; R G DeRegis; D A Behr
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191
View more
  10 in total

Review 1.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

2.  In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.

Authors:  Barbara A Brown-Elliott; Jessica Killingley; Sruthi Vasireddy; Linda Bridge; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

3.  Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.

Authors:  Qing-Tao Zhou; Bei He; Ning Shen; Ying Liang; Li-Na Sun
Journal:  Drugs Aging       Date:  2017-02       Impact factor: 3.923

4.  Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis.

Authors:  Elizabeth B Burgener; Johanna M Sweere; Michelle S Bach; Patrick R Secor; Naomi Haddock; Laura K Jennings; Rasmus L Marvig; Helle Krogh Johansen; Elio Rossi; Xiou Cao; Lu Tian; Laurence Nedelec; Søren Molin; Paul L Bollyky; Carlos E Milla
Journal:  Sci Transl Med       Date:  2019-04-17       Impact factor: 17.956

Review 5.  [Tissue penetration of antibiotics. Does the treatment reach the target site?].

Authors:  H Lagler; M Zeitlinger
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-02       Impact factor: 0.840

6.  Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.

Authors:  Michael Paal; Christina Scharf; Ann Katrin Denninger; Luis Ilia; Charlotte Kloft; Nikolaus Kneidinger; Uwe Liebchen; Sebastian Michel; Christian Schneider; Sebastian Schröpf; Carina Schuster; Michael Vogeser; Ferdinand Weinelt; Johannes Zander; Michael Zoller; Ines Schroeder
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

7.  Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.

Authors:  Jörn Grensemann; David Busse; Christina König; Kevin Roedl; Walter Jäger; Dominik Jarczak; Stefanie Iwersen-Bergmann; Carolin Manthey; Stefan Kluge; Charlotte Kloft; Valentin Fuhrmann
Journal:  Ann Intensive Care       Date:  2020-04-22       Impact factor: 6.925

8.  Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation.

Authors:  Xiangqing Song; Yi Wu; Lizhi Cao; Dunwu Yao; Minghui Long
Journal:  Front Microbiol       Date:  2019-11-29       Impact factor: 5.640

9.  Evaluation of a New Culture-Based AtbFinder Test-System Employing a Novel Nutrient Medium for the Selection of Optimal Antibiotics for Critically Ill Patients with Polymicrobial Infections within 4 h.

Authors:  George Tetz; Victor Tetz
Journal:  Microorganisms       Date:  2021-05-04

10.  Plasma and Renal Cortex Meropenem Concentrations in Patients Undergoing Percutaneous Renal Biopsy.

Authors:  Rodrigo A Sepúlveda; Patricio Downey; Dagoberto Soto; Kwok-Yin Wong; Yun-Chung Leung; Lok-Yan So; Max Andresen
Journal:  Biomed Res Int       Date:  2019-11-19       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.